Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 19/20 | 0.61 |
| ▸ | THRB | P10828 | 19/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620360 | 0.84 | THRA (0.42) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL2926289 | 0.82 | THRB (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749523 | 0.82 | THRA (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749414 | 0.82 | THRA (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22668218 | 0.80 | THRB (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749381 | 0.79 | THRA (0.64) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL24032552 | 0.79 | THRB (0.70) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22668215 | 0.79 | THRA (0.63) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632428 | 0.79 | THRA (0.66) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL29029719 | 0.78 | THRB (0.40) | THRATHRBCYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051925-A1 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2024-02-15 | — | — | US | disclosed |
| EP-4232436-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | Madrigal Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116406356-A | Process for the preparation of 6- (4-nitro-phenoxy) -2H-pyridazin-3-one and 6- (4-amino-phenoxy) -2H-pyridazin-3-one derivatives as intermediates for thyroid hormone analogues | 马德里加尔制药公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2022087141-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | MADRIGAL PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087141-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | MADRIGAL PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051925-A1 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | CYP7A1, LIPC, CYP11B2 | THRA 4272/4885THRB 3953/4885CYP2C9 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.